Skip to main content
OpenTrials

Clinical trial condition

Refractory Head and Neck Squamous Cell Carcinoma

Explore clinical trials studying Refractory Head and Neck Squamous Cell Carcinoma. Study availability and eligibility vary by location and protocol.

3 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Refractory Head and Neck Squamous Cell Carcinoma trial results

Recruiting

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

NCT06589804

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +38 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Fremont - Rideout Cancer Center Marysville, California, United States
  • VA Palo Alto Health Care System Palo Alto, California, United States
  • UCHealth Memorial Hospital Central Colorado Springs, Colorado, United States
View all 192 locations
View Trial Details
Recruiting

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

NCT06211335

Conditions
Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +8 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • University of Colorado Denver | Anschutz Medical Campus Aurora, Colorado, United States
View Trial Details

Related conditions